retatrutide clinical trial A New Obesity Drug Delivered Surgery-Level Weight Loss in Trials Lilly's 'triple G' agonist triumphs

Retatrutide produces more gastrointestinal distress but also delivers more weight loss as a monotherapy

Provincial drug coverage through programs like Ontarios OHIP+ or British Columbias PharmaCare will eventually factor in once Retatrutide receives formal approval, but those pathways are likely 2+ years away

Maybe your original day no longer works with your schedule

AI is significantly impacting the GLP-1 targeted peptide weight loss drugs market by accelerating drug discovery, optimizing clinical trials, and enhancing personalized treatment approaches

What the courts decide in this matter will affect the future of many plaintiffs in the Trulicity litigation

95% CI 0.38 0.99